Johnson & Johnson
DUS:JNJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Johnson & Johnson
DUS:JNJ
|
US |
|
Endesa SA
OTC:ELEZY
|
ES |
|
TFF Pharmaceuticals Inc
NASDAQ:TFFP
|
US |
|
Sanlam Ltd
OTC:SLMAF
|
ZA |
|
S
|
Sanyu Construction Co Ltd
TSE:1841
|
JP |
|
Q
|
Quetzal Copper Corp
XTSX:SICO
|
CA |
|
Capital One Financial Corp
NYSE:COF
|
US |
|
Piovan SpA
MIL:PVN
|
IT |
|
KGL Resources Ltd
ASX:KGL
|
AU |
|
First Commonwealth Financial Corp
NYSE:FCF
|
US |
|
Maxis Bhd
OTC:MAXSF
|
MY |
|
A
|
Aegon NV
MIL:AGN
|
NL |
|
A
|
Aviva PLC
XBER:GU8
|
UK |
|
Adani Total Gas Ltd
NSE:ATGL
|
IN |
|
Industrials REIT Ltd
LSE:MLI
|
UK |
|
Tetra Tech Inc
NASDAQ:TTEK
|
US |
|
A
|
Attendo AB (publ)
STO:ATT
|
SE |
|
Athena Bitcoin Global
OTC:ABIT
|
US |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
US |
Wall St Price Targets
JNJ Price Targets Summary
Johnson & Johnson
According to Wall Street analysts, the average 1-year price target for JNJ is 225.63 EUR with a low forecast of 149.67 EUR and a high forecast of 260.85 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is JNJ's stock price target?
Price Target
225.63
EUR
According to Wall Street analysts, the average 1-year price target for JNJ is 225.63 EUR with a low forecast of 149.67 EUR and a high forecast of 260.85 EUR.
What is the Revenue forecast for Johnson & Johnson?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 8 years is 4%.
What is the Operating Income forecast for Johnson & Johnson?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 8 years is 10%.
What is the Net Income forecast for Johnson & Johnson?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Net Income has been 7%. The projected CAGR for the next 8 years is 7%.
